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Background: More than 350 million people are chronic carriers of hepatitis B virus (HBV) and because of the high HBV-related morbidity and mortality, the global disease burden of HBV is substantial. In patients with HBeAg–negative chronic hepatitis B (CHB) with serum alanine aminotransferase (ALT) levels, 1-2 × upper limit of normal (ULN) and HBV DNA load of 10000 to 100000 copies/mL, liver biopsy should be considered and treatment may be initiated if liver biopsy shows moderate/severe necro-inflammation or significant fibrosis. A dynamic balance between viral replication and host immune response is pivotal for the pathogenesis of liver disease in HBV infection. Due to immune response variability, there is thought to be a considerable difference in the histopathologic status of liver biopsy samples present in various populations.
Objectives: Liver histopathology in asymptomatic patients with greater than 10000 DNA copies/mL despite negative Hbe Ag was studied to determine, the number of people that will benefit from a liver biopsy, and variables that will significantly be affected by viral load changes.
Patients and Methods: Eighty-two symptomless hepatitis B patients, identified during screening tests, were entered into the study. All candidates were HBS Ag Positive, Hbe Ag negative, Hbe Ab positive, HDV Ab, HIV Ab 1, 2, and HCV Ab negative. In all cases HBV DNA virus load was greater than 10000 copies/mL (2000 U/mL). Liver biopsy was done after obtaining a written consent. Liver histopathology was reported based on the histological activity index (HAI).
Results: Both HBV DNA load and serum ALT levels significantly correlated with the grade score. Both stage and grade significantly correlated with age. Stage score of liver specimens was significantly lower in women than men. Logistic regression analysis indicated that the baseline ALT and HBV DNA levels and age were independent predictors of the HAI score.
Conclusions: In 10% of the patients, liver biopsy changed the treatment plan and treatment was started despite ALT levels being less than twice the normal level.
Keywords:Hepatitis B Virus; Pathology; Chronic
Implication for health policy/practice/research/medical education:In patients with asymptomatic chronic hepatitis B, liver biopsy may change the therapeutic options in some of them, and there are some predictor fac-tors for liver pathologic score.Copyright © 2013, Infectious Diseases and Tropical Medicine Research Center; Published by Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. BackgroundHepatitis B virus (HBV) is a serious public health prob-lem worldwide. More than 350 million people are chron-ic carriers of HBV and because of high HBV-related mor-bidity and mortality, the global disease burden of HBV is substantial (1). In China, for example, Hepatitis B imposes a considerable economic burden on a family as the sum of direct medical and nonmedical costs, ranging from 30.72% (for acute hepatitis B) to 297.85% (for primary liver cancer) of the average annual household income (2). The prevalence of chronic HBV infection varies geographical-ly, from high (> 8%) to intermediate (2-7%) and low (< 2%) 
prevalence. The Islamic Republic of Iran is a country in which hepatitis B prevalence is at the intermediate level (3). In the Ardabil province HBsAg positive prevalence rate among blood donors has been 1.4% (4).A dynamic balance between viral replication and host immune response is pivotal to the pathogenesis of liver disease in HBV infection (5). Furthermore, environmen-tal factors like alcohol consumption, and viral factors in-cluding genotype of the virus and presence of mutations in core and precore promoters may affect the viral load (6, 7). In HBeAg–negative patients, it is difficult to define 
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a single cutoff HBV DNA value for differentiating inactive carriers from patients with HBeAg-negative chronic hep-atitis (6), thus liver biopsy has been used as a last resort. In patients with HBeAg–negative CHB, treatment should be considered if ALT is > 2 × ULN and HBV DNA is > 2000 IU/mL. If ALT is 1-2 × ULN and DNA is 2000-20 000 IU/mL, liver biopsy should be considered and treatment may be initiated if liver biopsy shows moderate/severe necro-in-flammation or significant fibrosis (8).
2. ObjectivesDue to immune response variability, there is thought to be a considerable difference in the histopathologic status of liver biopsy samples present in various populations. Thus, the present study evaluated liver histopathological status of patients with high DNA copy loads in their se-rum despite negative HbeAg, to determine the number of people that will benefit from a liver biopsy and the vari-ables that are significantly affected by viral load changes.
3. Patients and MethodsDuring a one-year period in a cross sectional study, all symptomless hepatitis B patients, identified during screening tests (for blood donation, pregnancy, surgery, etc) were evaluated. All of the following, HBsAg, HbeAg, Hbe Ab, HIV Ab 1, 2, and HCV Ab were checked. HBV DNA virus load was checked in our hospital’s genetic labora-tory. All of the HBsAg Positive patients with negative HbeAg (positive Hbe Ab), negative HDV Ab, negative HIV Ab 1, 2 and negative HCV Ab, provided that they had a HBV DNA virus load greater than 10000 copies/mL (2000 U/mL), were entered in the study. According to routine rec-ommendations in management of chronic hepatitis B, liver biopsy was done for all candidates after obtaining a written consent. All of the specimens, were histopatho-logically examined by one expert pathologist, based on Histological Activity Index (HAI) (9).Sonographic examination of the liver was done to rule out cirrhosis and biopsy contraindication. Exclusion cri-teria for patients in this study were; alcoholism, history of antiviral therapy in the past, simultaneous infection with HIV or HCV. DNA viral load was measured quantita-tively using the Primer Design™ genesig Kit for Hepatitis B Virus (HBV) Genomes with 100% homology in a broad range of clinically relevant reference sequences, and high priming efficiency of > 95% to detect less than 100 copies of the target template.Antibody detection was done using the Chemilumines-cence technique. All of the collected data were saved con-fidentially and analyzed via the SPSS software (version 16) using the chi-square and independent samples t-tests and the linear regression model. P values less than 0.05 were considered statistically significant.
4. ResultsEighty-two patients were evaluated during this study with a mean age of 35.01 ± 11.7 years (19-77) and 47 being male (57.3%) and 35 female (42.7%). The mean amount for serum ALT level and HBV-DNA copies per mL (Multiply in 10000) were 65.23 ± 20.13 U/mL (11-147) and 6523.44 ± 34387.37 copies/mL, respectively. History of chronic hepa-titis B in at least one other family member in 35 patients (42.7%) and carrier state in mother in 8% (9.8%) of patients were positive. Others had no information about hepati-tis B status of their family. At the time of diagnosis, all of the patients were clinically asymptomatic. Histopatho-logical report of liver biopsies was provided based on the Knodell Score. Mean ± SD for grade and stage of HAI were 4.4 ± 3.3 and 0.44 ± 0.81, respectively. To detect the relationship between the two variables, linear regression was used. A linear regression line is described by the fol-lowing equation; Y = a + bX, where X is the explanatory variable and Y is the dependent variable. The slope of the line is b, and a, is the intercept (the value of y when x = 0). P value < 0.05 means 95% Confidence interval for b, does not include 0.Among variables, both HBV DNA load and serum ALT lev-els significantly correlated with grade of HAI. Both stage and grade significantly correlated with age, but P value for stage was more significant (Table 1). Among patients with less than twice the normal levels of ALT, consisting of 42 males (51.2%) and 29 females (35.3%), liver biopsy results were interesting and about 15% of men and 7% of women needed treatment (Tables 2 -5). Another interesting find-ing of the study was the significant difference in the liver stage index of liver biopsies between men and women. Despite the absence of a significant mean difference in vi-ral DNA load, serum ALT and age among the two sexes (P = 0.127, P = 0.22 and P = 0.96 respectively, t test), stage scores in liver specimen biopsies were significantly lower in women than men and stages greater than score 1 were not seen in women. Difference in histopathological status of the liver among sexes was limited to stages and statistical differences were not seen in grade or total HAI. Chi-square test values for determination of significant differences in histological status including stage, grade and total HAI among sexes were 0.024, 0.485, and 0.228, respectively.Logistic regression analysis indicated that the baseline ALT, HBV DNA levels and age were independent predictors of the HAI score. To describe the relationship between the three explanatory variables (age, ALT and HBV DNA load) and the response variable (HAI) multiple linear re-gression was used and a regression equation with a rela-tively low R-Squared (0.20) was obtained (if R-Squared = 1.0, then given the value of one term, one can perfectly predict the value of another term and if R-Squared = 0.0, then knowing one term does not help with determining the other term).
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HAI = -0.455 + 0.72 log (HBV DNA/10000) + 0.075 (Age) + 0.029 (ALT)This means that in asymptomatic CHB patients with greater than 10000/mL HBV DNA copies/mL, every 10000 
copies increase in HBV DNA load, or 10 years increase in age, and/or 25 U/mL increase in serum ALT level, can rise HAI by 0.7. For example in a 50-year-old man with serum ALT = 70 and HBV DNA level = 108, HAI is expected to be equal to 5.
Table 1.  Relationship Between the Three Explanatory Variables a
Dependent Vari-
able: Y
Explanatory Vari-
able: X
Unstandardized Coefficients Correlation Coef-
ficient: ρ
P Value
Slope of the Line (b) Value of y When x = 0 (a)
Grade score Log (HBV/10000) 0.7 2.8 0.35 0.001
Grade score ALT 0.02 2.9 0.31 0.004
Stage score Age 0.01 -0.19 0.25 0.02
Grade score Age 0.5 2.2 0.22 0.04
HAI Age 0.07 2.04 0.24 0.02a Abbreviations: ALT, alanine aminotransferase; HAI, histological activity index.
Table 2.  HAI Stage Score for Men With ALT Levels Less Than Twice the Normal Level
Stage score Frequency Valid Percentage Cumulative Percentage
0 34 81.0 81.0
1 5 11.9 92.9
3 2 4.8 97.6
5 1 2.4 100.0
Total 42 100.0
Table 3.  HAI Grade Score for Men With ALT Levels Less Than Twice the Normal Level
Grade score Frequency Valid Percentage Cumulative Percentage
1 7 16.7 16.7
2 8 19.0 35.7
3 8 19.0 54.8
4 6 14.3 69.0
5 3 7.1 76.2
6 4 9.5 85.7
7 1 2.4 88.1
8 2 4.8 92.9
10 2 4.8 97.6
12 1 2.4 100.0
Total 42 100.0
Table 4.  HAI Stage Score for Women With ALT Levels Less Than Twice the Normal Level
Stage score Frequency Valid Percentage Cumulative Percentage
0 16 55.2 55.2
1 13 44.8 100.0
Total 29 100.0
Table 5.  HAI Grade Score for Women With ALT Levels Less Than Twice the Normal Level
Grade Score Frequency Valid Percentage Cumulative Percentage
0 1 3.4 3.4
1 5 17.2 20.7
2 7 24.1 44.8
3 2 6.9 51.7
4 1 3.4 55.2
5 5 17.2 72.4
6 6 20.7 93.1
7 1 3.4 96.6
9 1 3.4 100.0
Total 29 100
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5. DiscussionIn the present study both HBV DNA load and serum ALT levels significantly correlated with grade of HAI (but not with stage). Both stage and grade significantly correlated with age. HAI stages in liver specimen biopsies were sig-nificantly lower in women than men and stages greater than one were not seen in women. Logistic regression analysis indicated that the baseline ALT and HBV DNA lev-els and age were independent predictors of the HAI score.In the present study, both HBV DNA load and serum ALT levels significantly correlated with grade of HAI (but not with stage). Correlation between ALT and HAI has been evaluated previously by some other studies in Iran. In a cross-sectional study of 146 CHB patients, by Babamah-moodi et al. 94 were HBeAg negative and 52 were HBeAg positive and there was a significant relationship between HBV-DNA level and ALT enzyme (10). Review of 86 hepatic biopsies by Semnani et al. also showed a significant re-lationship between AST, ALT serum levels and Knodell HAI quantitative scores (P < 0.05) (11). Using summative methodology, statistically significant and consistent cor-relations between viral load level or change and histo-logical grading and biochemical and serologic response were shown in 26 prospective studies (12). Viraemia levels also reflect the clinical stages of chronic hepatitis B virus (HBV) infection, in 'healthy carriers’. Increasing HBV DNA level was associated with significantly higher inflamma-tion and fibrosis in HAI scores and higher ALT (ALT / the upper reference value) (13).In the present study, both stage and grade significantly correlated with age. HAI stages in liver specimen biopsies were significantly lower in women than men. In a cohort of 70 Caucasian patients with chronic hepatitis B, older age, male sex, cirrhosis at entry and absence of sustained remission predicted liver-related death, independently. The risk of liver-related mortality in Caucasian adults with chronic hepatitis B is strongly related to sustained disease activity and ongoing high level of HBV replica-tion independent of HBeAg status (14).Normal ALT itself is not a reliable marker for taking the right decision and liver biopsy can detect a considerable number of patients who need treatment (15). Kumar et al. showed that in HBeAg negative patients with chronic HBV infection with persistently normal ALT, 13% have fi-brosis stage ≥ 2 and a fair proportion of such subjects have significant liver damage. They also declared that 35.3% of HBeAg-negative cases that were incidentally de-tected as asymptomatic HBsAg-positive patients with persistently normal ALT, had baseline HBV DNA levels ≥ 5-log copies/mL; 39.7% had HAI > 3; and 13.8% had fibrosis stage≥ 2 on histology (16). Thus, a cutoff point for HBV DNA load for anticipating probable liver damage in CHB patients has been suggested. In the present study, by considering a cut-off point of seven for grade and two for stage as a treatment onset point for patients with ALT levels less than twice the normal level, about 15% of 
men and 7% of women needed to be treated. Higher HAI stage in men in comparison with women may be due to some other virulence factors such as diet, job, hormonal effects, drug consumption and etc.Overall, at least in 10% of these patients, liver biopsy changed treatment options and treatment was initiated despite ALT levels being less than twice the normal level. In our HBeAg-negative CHB patients with greater than 10000 copies/mL HBV DNA, male sex, higher age, higher viral load and higher ALT significantly correlated with HAI. HAI stages in liver specimen biopsies were signifi-cantly lower in women than men.
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